A5037261029- CAR-T cell therapy research
- CRISPR and Genetic Engineering
- Pluripotent Stem Cells Research
- Evolution and Genetic Dynamics
- T-cell and B-cell Immunology
- Single-cell and spatial transcriptomics
- Cancer Genomics and Diagnostics
- Acute Myeloid Leukemia Research
- Epigenetics and DNA Methylation
- Chronic Lymphocytic Leukemia Research
- Viral Infectious Diseases and Gene Expression in Insects
- Monoclonal and Polyclonal Antibodies Research
- Gene Regulatory Network Analysis
University of California, San Francisco
2023-2025
Stanford University
2023
CRISPR-Cas9 genome editing has enabled advanced T cell therapies, but occasional loss of the targeted chromosome remains a safety concern. To investigate whether Cas9-induced is universal phenomenon and evaluate its clinical significance, we conducted systematic analysis in primary human cells. Arrayed pooled CRISPR screens revealed that was generalizable across resulted partial entire chromosome, including preclinical chimeric antigen receptor cells with persisted for weeks culture,...
CRISPR-Cas9 genome editing has enabled advanced T cell therapies, but occasional loss of the targeted chromosome remains a safety concern. To investigate whether Cas9-induced is universal phenomenon and evaluate its clinical significance, we conducted systematic analysis in primary human cells. Arrayed pooled CRISPR screens revealed that was generalizable across resulted partial entire chromosome, including pre-clinical chimeric antigen receptor cells with persisted for weeks culture,...
Abstract Engineering T cell specificity and function at multiple loci can generate more effective cellular therapies, but current manufacturing methods produce heterogenous mixtures of partially engineered cells. Here we develop a one-step process to enrich unlabeled cells containing knock-ins target using family repair templates named synthetic exon expression disruptors (SEEDs). SEEDs associate transgene integration with the disruption paired endogenous surface protein while preserving in...
CRISPR-Cas9 genome editing has enabled advanced T cell therapies, but occasional loss of the targeted chromosome could be a safety concern. To investigate whether Cas9-induced is universal phenomenon and evaluate its clinical significance, we conducted systematic analysis in primary human cells. Arrayed pooled CRISPR screens revealed that partial or entire after DNA cutting rare generalized phenomenon, occurring also pre-clinical chimeric antigen receptor cells with persist for weeks...
Abstract Antibodies and B-cell receptors (BCRs) are produced by B cells, built of a heavy chain light chain. Although each cell could express two different chains four chains, usually only unique pair is expressed—a phenomenon known as allelic exclusion . However, small fraction naive-B cells violate expressing productive one which has impaired function; this been called inclusion We demonstrate that these can be used to learn constraints on antibody sequence. Using large-scale single-cell...